[go: up one dir, main page]

UY26787A1 - 3-AZABICICLO DERIVATIVES (3.1.0.) HEXANO USEFUL IN THERAPY - Google Patents

3-AZABICICLO DERIVATIVES (3.1.0.) HEXANO USEFUL IN THERAPY

Info

Publication number
UY26787A1
UY26787A1 UY26787A UY26787A UY26787A1 UY 26787 A1 UY26787 A1 UY 26787A1 UY 26787 A UY26787 A UY 26787A UY 26787 A UY26787 A UY 26787A UY 26787 A1 UY26787 A1 UY 26787A1
Authority
UY
Uruguay
Prior art keywords
useful
derivatives
azabiciclo
hexano
therapy
Prior art date
Application number
UY26787A
Other languages
Spanish (es)
Inventor
Ashley Edward Fenwick
Bernard Joseph Banks
Douglas James Critcher
David Morris Gethin
Stephen Paul Gibson
Mr Graham Lunn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY26787A1 publication Critical patent/UY26787A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Compuestos de la fórmula I, en la que los sustituyentes son como se definieron en la presente, y los derivados o profármacos farmacéutica o veterinariamente aceptables de éstos son farmaceútica y veterinariamente útiles, en particular, se unen a receptores opiáceos (por ejemplo receptores opiáceos mu, kappa y delta ). Es probable que sean útiles en el tratamiento de enfermedades o afecciones moduladas por receptores opiáceos, por ejemplo síndrome del intestino irritable, estrenimiento, náuseas, vómitos, prurito, trastornos alimentarios, sobredosis opiáceas, depresión, adicción al tabaco y al alcohol, disfunción sexual, shock, apoplejía, dano espinal y trauma cerebral.Compounds of the formula I, in which the substituents are as defined herein, and the pharmaceutically or veterinarily acceptable derivatives or prodrugs thereof are pharmaceutically and veterinarily useful, in particular, bind to opioid receptors (eg mu opiate receptors , kappa and delta). They are likely to be useful in the treatment of diseases or conditions modulated by opioid receptors, for example irritable bowel syndrome, constipation, nausea, vomiting, pruritus, eating disorders, opioid overdose, depression, tobacco and alcohol addiction, sexual dysfunction, shock, stroke, spinal damage and brain trauma.

UY26787A 2000-06-23 2001-06-21 3-AZABICICLO DERIVATIVES (3.1.0.) HEXANO USEFUL IN THERAPY UY26787A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015562.2A GB0015562D0 (en) 2000-06-23 2000-06-23 Heterocycles
PCT/IB2001/001035 WO2001098267A1 (en) 2000-06-23 2001-06-07 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity

Publications (1)

Publication Number Publication Date
UY26787A1 true UY26787A1 (en) 2002-01-31

Family

ID=9894368

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26787A UY26787A1 (en) 2000-06-23 2001-06-21 3-AZABICICLO DERIVATIVES (3.1.0.) HEXANO USEFUL IN THERAPY

Country Status (34)

Country Link
EP (1) EP1292574A1 (en)
JP (1) JP2004512263A (en)
KR (1) KR20040002386A (en)
CN (1) CN1639121A (en)
AP (1) AP2002002698A0 (en)
AR (1) AR028969A1 (en)
AU (1) AU781837B2 (en)
BG (1) BG107329A (en)
BR (1) BR0111867A (en)
CA (1) CA2412188A1 (en)
CZ (1) CZ20023967A3 (en)
DO (1) DOP2001000187A (en)
DZ (1) DZ3368A1 (en)
EA (1) EA005117B1 (en)
GB (1) GB0015562D0 (en)
HR (1) HRP20020998A2 (en)
HU (1) HUP0301228A3 (en)
IL (1) IL153427A0 (en)
IS (1) IS6637A (en)
MA (1) MA26915A1 (en)
MX (1) MXPA02012878A (en)
NO (1) NO20026168L (en)
NZ (1) NZ523141A (en)
OA (1) OA12293A (en)
PA (1) PA8519401A1 (en)
PE (1) PE20020253A1 (en)
PL (1) PL365956A1 (en)
SK (1) SK17172002A3 (en)
TN (1) TNSN01094A1 (en)
UA (1) UA73176C2 (en)
UY (1) UY26787A1 (en)
WO (1) WO2001098267A1 (en)
YU (1) YU91802A (en)
ZA (1) ZA200210278B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12711A (en) * 2001-10-22 2006-06-27 Pfizer Prod Inc 3-AzabicycloÄ3.1.0Ühexane derivatives as opoioid receptor antagonists.
JP2005531557A (en) * 2002-05-17 2005-10-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Use of effective compounds as selective opiate receptor modulators
DE10259245A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivatives of asimadolin with covalently bound acids
RU2434011C2 (en) * 2004-02-23 2011-11-20 Глэксо Груп Лимитед Azabicyclo{3,1,0}hexane derivatives used as dopamine receptor d3 modulators
GB0507680D0 (en) 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
US7807698B2 (en) 2005-06-14 2010-10-05 Glaxo Group Limited Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
WO2007113258A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
RU2441655C2 (en) 2007-03-30 2012-02-10 Тиога Фармасьютикалз Инк. Kappa-opioid agonists for treatment of diarrhea-prevailing irritable bowel syndrome and alternate irritable bowel syndrome
TWI423801B (en) * 2007-08-27 2014-01-21 Theravance Inc 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
WO2011154827A2 (en) 2010-06-11 2011-12-15 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
JP2013542929A (en) 2010-09-28 2013-11-28 パナセア バイオテック リミテッド New bicyclo ring compounds
MX2016006482A (en) 2013-11-20 2016-12-09 Sanwa Kagaku Kenkyusho Co Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes.
CA2985327A1 (en) 2015-05-20 2016-11-24 Sanwa Kagaku Kenkyusho Co., Ltd. Crystal of salt of 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof
CA3052479A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
JP7316216B2 (en) * 2017-02-17 2023-07-27 トレベナ・インコーポレイテッド Delta-opioid receptor modulating compounds containing 5-membered azaheterocycles, methods of use and preparation thereof
CN110352055A (en) 2017-03-02 2019-10-18 株式会社三和化学研究所 Medications for Alcohol Use Disorder
CN108250088B (en) * 2018-01-04 2020-10-30 四川之江高新材料股份有限公司 The preparation method of N,N,N'-trimethyl-N'-hydroxyethyl bisaminoethyl ether
CN115825305B (en) * 2022-10-21 2024-09-20 昆明理工大学 Molecularly imprinted solid-phase microextraction fiber and preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065230A (en) * 1959-03-16 1962-11-20 Burroughs Wellcome Co Azabicyclohexanes and method of preparing them
PH24752A (en) * 1987-04-16 1990-10-01 Lilly Co Eli Piperidine opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
DE4341403A1 (en) * 1993-12-04 1995-06-08 Basf Ag N-substituted 3-azabicycloalkane derivatives, their preparation and use
PE20001420A1 (en) * 1998-12-23 2000-12-18 Pfizer CCR5 MODULATORS
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy

Also Published As

Publication number Publication date
EA005117B1 (en) 2004-10-28
TNSN01094A1 (en) 2005-11-10
ZA200210278B (en) 2003-12-19
EP1292574A1 (en) 2003-03-19
NZ523141A (en) 2005-06-24
WO2001098267A8 (en) 2003-02-27
JP2004512263A (en) 2004-04-22
GB0015562D0 (en) 2000-08-16
NO20026168L (en) 2003-02-18
BG107329A (en) 2003-07-31
WO2001098267A1 (en) 2001-12-27
MXPA02012878A (en) 2003-05-14
AR028969A1 (en) 2003-05-28
HRP20020998A2 (en) 2004-02-29
CZ20023967A3 (en) 2004-02-18
EA200201269A1 (en) 2003-06-26
PA8519401A1 (en) 2002-12-30
UA73176C2 (en) 2005-06-15
PL365956A1 (en) 2005-01-24
YU91802A (en) 2006-05-25
HUP0301228A2 (en) 2003-08-28
IL153427A0 (en) 2003-07-06
CA2412188A1 (en) 2001-12-27
NO20026168D0 (en) 2002-12-20
SK17172002A3 (en) 2004-09-08
AP2002002698A0 (en) 2002-12-31
PE20020253A1 (en) 2002-04-08
AU781837B2 (en) 2005-06-16
CN1639121A (en) 2005-07-13
KR20040002386A (en) 2004-01-07
BR0111867A (en) 2003-07-01
MA26915A1 (en) 2004-12-20
HUP0301228A3 (en) 2005-08-29
AU6259101A (en) 2002-01-02
IS6637A (en) 2002-11-28
OA12293A (en) 2004-03-18
DOP2001000187A (en) 2002-03-30
DZ3368A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
UY26787A1 (en) 3-AZABICICLO DERIVATIVES (3.1.0.) HEXANO USEFUL IN THERAPY
MXPA04004370A (en) Polycyclic guanine derivative phosphodiesterase v inhibitors.
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
TW200503713A (en) Novel compounds
BR0316753A (en) Treatment method for sexual dysfunction
GB0329214D0 (en) Novel compounds
CA2422698A1 (en) Indoline derivatives and their use as 5-ht2 receptor ligands
GT200100147A (en) IMIDAZOL DERIVATIVES
CR9622A (en) DERIVATIVES OF PIRAZOLO [3,4-D] AZEPIN AS HISTAMINE ANTAGONISTS H3
ECSP056202A (en) DERIVATIVES OF IMIDAZOL AS ANTAGONISTS OF THE GLUTAMATE RECEIVER
BR0308567A (en) apomorphine glycoside and orthoester glycoside derivatives, analogs, and their uses
TW200611701A (en) Novel compounds
PT1736157E (en) Morphinan derivatives as anti-itching agent
PA8592801A1 (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
MX2007006754A (en) Indenyl derivatives and use thereof for the treatment of neurological disorders.
WO2007128827A8 (en) 17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies
ECSP014079A (en) SULFONAMIDE DERIVATIVES
SV2002000459A (en) DERIVATIVES OF SULFONAMIDS REF. X-13840
GB0317491D0 (en) Organic compounds
TW200621223A (en) Acyclic 1,3-diamines and uses therefor
BR0202768A (en) 1-Diphenylmethyl-pyrazole derivatives as opiate receptor ligands
MXPA05001967A (en) Process for producing indolopyrrolocarbazole derivative.
ATE491473T1 (en) PAIN RELIEVING ASSOCIATION WITH A DIHYDROIMIDAZOPYRAZINE DERIVATIVE
UA92330C2 (en) 2-acylaminothiazole derivatives
DOP2004000920A (en) IMIDAZOL DERIVATIVES AS GLUTAMATE RECEIVER ANTAGONISTS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140212